GlobeNewsWire
08 Jun 2026, 10:30 UTC · 3h ago
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
GlobeNewsWire
08 Jun 2026, 10:30 UTC · 3h ago
Story key points
4 claims · impact-rated
The FDA granted RMAT designation to AlloNK in combination with rituximab for the treatment of refractory rheumatoid arthritis (RA). — RMAT designation provides expedited review and development benefits, significantly accelerating the potential path to commercialization for a high-need indication.
+0.80In a Phase 2a basket trial for refractory RA, 71% of patients with six months of follow-up achieved an ACR50 response. — High clinical efficacy (ACR50) in a refractory population provides strong proof-of-concept for the therapy's viability and market potential.
+0.70Artiva's recent financing is expected to extend its cash runway into 2029. — Extended runway reduces immediate dilution risk and provides the financial stability necessary to execute a Phase 3 trial.
+0.50Continue reading
6 related stories
Top 3 movers · tap to explore
Clinical data from 31 patients across RA, Sjögren disease, and systemic sclerosis showed clinically meaningful improvements in disease activity. — Success across multiple B-cell driven diseases suggests a broader total addressable market beyond just RA.
+0.40Ticker attribution
Model heads
Positive clinical data presented at EULAR 2026 and receipt of FDA RMAT designation for its AlloNK therapy.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
WSJ
4h ago
